Ivermectin B1b is a minor component of Ivermectin (I940800), a semi-synthetic derivative of Abamectin; consists of a mixture of not less than 80% component B1a and not more than 20% component B1b. Antihelmintic (Onchocerca). An invitro inhibitor of SARS-CoV-2/ Covid-19.
Ivermectin B1b (dihydroavermectin B1b) is the minor component (<20%) of the commercial anthelmintic, ivermectin. Members of the avermectin/milbemycin anthelmintic class exert their anthelmintic effects by binding to glutamate-gated chloride channels expressed on nematode neurones and pharyngeal muscle cells. The avermectin/milbemycins are also potent insecticides. In vitro, the B1b (25-iso-propyl) analogue is slightly more potent than the 25-sec-butyl (B1a) analogue as an inhibitor of nematode larval development and paralysis, and also a more sensitive probe for ivermectin resistance.
ChEBI: A macrocyclic lactone that is avermectin B1b in which the double bond present in the spirocyclic ring system has been reduced to a single bond. It is the minor component of ivermectin.
